How an Emerging Biopharma Preparing for Its First Launch Avoided Costly Early Investment

CUSTOMER STORY

How an Emerging Biopharma Preparing for
Its First Launch Avoided Costly Early Investment

Solution area

40+ field reps

Thereupeutic area

Commercial operations Oncology

Company

An emerging biopharma company developing rare disease therapies was preparing for its first launch while building out its commercial team

CHALLENGES

As the company moved closer to launch, readiness became a high-stakes balancing act. The team faced a critical question: How much to build before approval, and when to invest.

Several factors made that decision difficult.

Approval timing could shift at any moment

Accelerated approval created opportunity, but also uncertainty. Investments in data, systems, and hiring had to move forward without a fixed timeline.

Every early investment carried real cost risk

Hiring too soon or standing up systems too early could leave teams and infrastructure sitting idle, with no guarantee of when they'd be needed.

Waiting too long created execution pressure

Delaying decisions increased the risk of compressed timelines and rushed execution. At the same time, the commercial, medical, and analytics organization was still being built.

Our Approach

“At this stage, it comes down to three things: How much to build before approval? What insight is needed now to guide launch decisions? And how to invest without moving too early?”
Melissa McDevitt, Partner, Beghou

To balance readiness with uncertainty, the team built their decisions around a single anchor: a defined launch readiness milestone tied to expected approval. Rather than building continuously, every investment was evaluated against one question: what needs to be live at launch?

Defined the readiness milestone first

The team aligned on a clear readiness window ahead of expected approval. This gave every function a concrete point to plan against, reducing the risk of building too early or reacting too late.

Anchored every investment decision to that milestone

Hiring, systems, and vendor commitments were evaluated against what needed to be live at launch. If something wouldn't be used at that point, it was pushed out. This kept spend focused and prevented capabilities from sitting idle.

Used patient-level data to guide early choices

Instead of beginning with broader datasets, the team mapped how patients moved from diagnosis to treatment. This shaped physician prioritization, early engagement strategy, and forecast assumptions before broader data investments were made.

Aligned teams and built for post-launch scale

Commercial, medical, and analytics teams were onboarded to shared data and workflows early, so decisions stayed consistent across functions. Systems were selected based on what would still work after launch, avoiding short-term fixes and future rework.

IMPACT

Entered launch fully prepared, without the cost of building too early

Core systems, data, and workflows were in place at T-3 months, with no idle teams
or infrastructure waiting on approval.

Avoided rework and duplicate spend

Prioritizing patient-level data early meant no datasets to swap out, no vendor decisions
to revisit, and no last-minute gaps to close under pressure.

Launched with teams already working as one

Commercial, medical, and analytics teams were aligned on shared data and workflows
before launch day, with no coordination scramble at the finish line.

Do you know what truly needs to be in place before launch, and what can wait?

Beghou helps biopharma teams align investment decisions to real approval timelines, so they can reach launch readiness without unnecessary early cost.

Prepare for launch

The Beghou difference

The Beghou Arc Platform